Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GeneDx Holdings (WGS) EBITDA (2020 - 2025)

GeneDx Holdings (WGS) has disclosed EBITDA for 6 consecutive years, with -$17.7 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA fell 431.44% to -$17.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$20.9 million, a 59.69% increase, with the full-year FY2025 number at -$20.9 million, up 59.69% from a year prior.
  • EBITDA was -$17.7 million for Q4 2025 at GeneDx Holdings, down from -$7.4 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $32.7 million in Q3 2021 to a low of -$308.8 million in Q4 2022.
  • A 5-year average of -$52.1 million and a median of -$34.6 million in 2021 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: skyrocketed 157.81% in 2021, then tumbled 668.35% in 2022.
  • GeneDx Holdings' EBITDA stood at -$40.2 million in 2021, then crashed by 668.35% to -$308.8 million in 2022, then skyrocketed by 91.79% to -$25.3 million in 2023, then skyrocketed by 121.11% to $5.4 million in 2024, then plummeted by 431.44% to -$17.7 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's EBITDA are -$17.7 million (Q4 2025), -$7.4 million (Q3 2025), and $10.7 million (Q2 2025).